about
Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice.Gene therapy approaches for cardiovascular diseases.Characterization of proximal pulmonary arterial cells from chronic thromboembolic pulmonary hypertension patients.Role for telomerase in pulmonary hypertensionLong-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy.Chemotherapy-induced pulmonary hypertension: role of alkylating agents.Progressive Vascular Functional and Structural Damage in a Bronchopulmonary Dysplasia Model in Preterm Rabbits Exposed to Hyperoxia.BMPRII influences the response of pulmonary microvascular endothelial cells to inflammatory mediators.Amorphous silica nanoparticles promote monocyte adhesion to human endothelial cells: size-dependent effect.Extracellular Calpain/Calpastatin Balance Is Involved in the Progression of Pulmonary Hypertension.Rescuing BMPR2-driven endothelial dysfunction in PAH: a novel treatment strategy for the future?Identification of the phospholipase A(2) isoforms that contribute to arachidonic acid release in hypoxic endothelial cells: limits of phospholipase A(2) inhibitors.Osteopontin, a Key Mediator Expressed by Senescent Pulmonary Vascular Cells in Pulmonary Hypertension.Letter by Belge et al Regarding Article, "Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Models".Contribution of inflammation and impaired angiogenesis to the pathobiology of chronic thromboembolic pulmonary hypertension.Is inflammation a potential therapeutic target in chronic thromboembolic pulmonary hypertension?NF-κB pathway is involved in CRP-induced effects on pulmonary arterial endothelial cells in chronic thromboembolic pulmonary hypertension.Ultrastructural localization of the small GTP-binding protein Rap1 in human platelets and megakaryocytes.Effects of C-reactive protein on human pulmonary vascular cells in chronic thromboembolic pulmonary hypertension.Evidence for Rap1 in vascular smooth muscle cellsHuman paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndromeDifferential up-regulation of Rap1a and Rap1b proteins during smooth muscle cell cycleSmooth muscle cell cycle and proliferation. Relationship between calcium influx and sarco-endoplasmic reticulum Ca2+ATPase regulationAbnormal cAMP-induced phosphorylation of rap 1 protein in grey platelet syndrome plateletsThe rat platelet 97-kDa Ca2+ATPase isoform is the sarcoendoplasmic reticulum Ca2+ATPase 3 proteinHypercholesterolemia impairs vascular remodelling after porcine coronary angioplastyMarkers of inflammation and disuse in vastus lateralis of chronic obstructive pulmonary disease patientsTGFβ and BMPRII signalling pathways in the pathogenesis of pulmonary arterial hypertensionCytokines trigger disruption of endothelium barrier function and p38 MAP kinase activation in BMPR2-silenced human lung microvascular endothelial cellsDouble-lung versus heart-lung transplantation for precapillary pulmonary arterial hypertension: a 24-year single-center retrospective studyCCR2/CCR5-mediated macrophage-smooth muscle cell crosstalk in pulmonary hypertensionLearning from registries in pulmonary arterial hypertension: pitfalls and recommendations
P50
Q33947837-B7FA56C2-3D64-4455-8352-29E38091BD71Q35794272-B01DA4A4-5042-4525-951D-DD6A2273366CQ35960192-0A826CE7-29B2-47E2-B51A-D8D643B48050Q36776314-30FE3648-8804-49D4-B531-7971F903D521Q37801153-04F94B91-CFB3-4890-BFF0-7221A4BF5673Q38286586-85BB5971-26A4-46CA-97AF-9322BC711AD9Q38376401-FF2A1D66-8D77-4542-BAE6-7DA7FDE4F807Q38732718-24CC551D-8876-4534-9C92-440634F32F4CQ39264437-7E93D3B0-BFB7-4984-96D9-F356E5C36378Q40855297-BF053E02-A6BD-45F4-9B28-7EA906E833A5Q42332332-95AAB00B-6526-4CAA-AEF3-D93D5682B03BQ42517280-633AC102-B79E-4877-B9E9-AA23659B7320Q51485537-3F48F8A0-3A06-4273-817D-CCC9D49BD2EAQ51535136-9391598A-BB85-45C5-8BEA-7A2B4F34C603Q51617923-236ADFA3-CF11-428B-B851-A93E35BFC70DQ51694056-71528F2A-57C6-49A8-B5D5-3528F9D04B7CQ53087784-C0720745-D3BE-4ABD-B55D-BB54D9DB52A7Q54023308-BC7943F9-D709-4010-9675-D2CAE0A91786Q54264173-5681B91E-4562-47BE-AB80-FB40AAEDFF13Q61150827-F5313FEB-6381-44D3-8ADF-A58D7ED5CE7CQ64377878-7431E14C-D186-4ACD-B031-8ECB1D062315Q71593278-92B2005F-E939-4A4A-9E82-B9AB06F58824Q71763062-8BF0C765-E8EA-428F-BD7A-7C49D7D302E8Q72490533-431DF31B-5659-4BFD-98D4-31E41D3E3C9CQ72725011-54DD470A-A9B6-4182-AF31-9C466BFAEAE5Q74477494-2FD3DAD2-5A81-4640-A10E-5D8149B3A032Q81328680-DBED096D-4CB6-4EE9-85A2-566C82DFA0B1Q90359833-E1C2858B-B237-43CD-94B1-ABFFB79E8F30Q91140225-5B439149-3C17-4B76-BDBC-4F10665C4B7FQ91421175-79C13818-B6C1-44AB-9F4A-0BBEF517FC82Q92000990-F2FF129A-05C8-41C1-986F-189E92D70C52Q92093492-F16A093D-197A-4A31-9163-9A701FAB0DEB
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Rozenn Quarck
@ast
Rozenn Quarck
@en
Rozenn Quarck
@es
Rozenn Quarck
@nl
type
label
Rozenn Quarck
@ast
Rozenn Quarck
@en
Rozenn Quarck
@es
Rozenn Quarck
@nl
prefLabel
Rozenn Quarck
@ast
Rozenn Quarck
@en
Rozenn Quarck
@es
Rozenn Quarck
@nl
P214
P106
P214
P31
P496
0000-0002-8293-6261
P7859
viaf-315736367